Skip to content

Effectiveness of Direct Current Stimulation to the head combined with Vagus Nerve Stimulation in the ear for the treatment of women with menstrual migraine

Effectiveness of Transcranial direct current stimulation (tDCS) combined with Transcutaneous auricular vagus nerve stimulation (taVNS) for the treatment of women with Menstrual migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-39c6cxy
Enrollment
52
Registered
2026-05-20
Start date
2025-09-04
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disorders Complicated migraine

Interventions

This is a randomized, open-label, controlled clinical trial composed of two groups of women, sham and intervention. An estimated 52 participants are expected, with the study comprising an intervention

Sponsors

Centro de Ciências da Saúde da Universidade Federal do Espírito Santo
Lead Sponsor
Centro de Ciências da Saúde da Universidade Federal do Espírito Santo
Collaborator

Eligibility

Sex/Gender
Female
Age
17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Cisgender women; aged 18 to 65 years; diagnosed with Menstrual Migraine according to the 2018 criteria of The International Classification of Headache Disorders (ICHD-3) for more than 3 months; attacks in menstruating women meeting ICHD-3 criterion B; attacks (without treatment or with ineffective treatment) occurring exclusively on day 1 ± 2 (i.e., days -2 to +3) of menstruation, in at least two of three menstrual cycles; and, additionally, at other times during the cycle

Exclusion criteria

Exclusion criteria: Peak cardiovascular disease or severe cardiopulmonary disease; with sequelae of neurological diseases; who use walking aids; who have visual and auditory impairments; amputations of lower and upper limbs; rheumatic diseases in the acute phase; cancer; epilepsy; fractures of the skull, cervical spine or rib cage; severe osteoporosis; use of a pacemaker and implantable cardioverter-defibrillator; who have undergone surgery less than 1 year ago; who have had a seizure in the last 1 year; pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frame
To assess the reduction in frequency and intensity of headaches in the intervention group compared to the sham group, using the Brief Pain Inventory and Pain Diary, considering a 2- point reduction in pain as a clinically significant outcome and a 50% reduction in frequency as a clinically significant outcome

Secondary

MeasureTime frame
No secondary outcomes are expected

Countries

BR

Contacts

Public ContactSynthia Marcolano

Universidade Federal do Espírito Santo

departamento.deis@ufes.br+55 (027) 3335-7201

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Jun 11, 2026